{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:29:45Z","timestamp":1784366985831,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Catechol-O-methyltransferase (COMT) is one of the main enzymes in dopamine metabolism and is reported to be associated with susceptibility to Parkinson\u2019s disease (PD) and pharmacotherapy. However, researchers mostly focus on the most common polymorphism, rs4680. In this case-control study, we investigated the association of SNPs other than rs4680 with the levodopa (L-dopa) response and other clinical features in Chinese PD patients. Eleven single nucleotide polymorphisms (SNPs) in the COMT gene were genotyped, and clinical data were collected. Patients with the TT genotype of rs165728 or rs174699 had larger daily levodopa equivalent doses (LEDs) than the patients with CC and CT genotypes under the dominant model (<jats:italic>p<\/jats:italic>\u2009=\u20090.01421 for rs165728 and <jats:italic>p<\/jats:italic>\u2009=\u20090.02302 for rs174699). Under the dominant model, the patients with GG at rs4680 G\u2009&gt;\u2009A had a lower occurrence of dyskinesia than those with AA and AG (<jats:italic>p<\/jats:italic>\u2009=\u20090.0196). Patients with CC at rs4633 had a lower occurrence of dyskinesia than those with TT and TC (<jats:italic>p<\/jats:italic>\u2009=\u20090.0429) under the dominant model. The frequencies of the rs174675 T and rs933271 C alleles were higher in PD patients than in the controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Our primary results showed the possible association of SNPs other than the most common functional rs4680 in COMT with interindividual variance in the L-dopa daily dose and susceptibility to dyskinesia in Chinese patients, although this was an exploratory study based on a small sample size. Larger and more randomized samples are necessary for further investigation.<\/jats:p>","DOI":"10.1038\/s41598-020-65332-2","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:03:06Z","timestamp":1591956186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson\u2019s disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Cuiping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxian","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"65332_CR1","doi-asserted-by":"publisher","first-page":"E551","DOI":"10.3390\/ijms18030551","volume":"18","author":"R Cacabelos","year":"2017","unstructured":"Cacabelos, R. Parkinson\u2019s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 18, E551, https:\/\/doi.org\/10.3390\/ijms18030551 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"65332_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri, K. R. & Schapira, A. H. Non-motor symptoms of Parkinson\u2019s disease:dopaminergic pathophysiology and treatment. Lancet Neurol. 8, 464\u2013474, https:\/\/doi.org\/10.1016\/S1474-4422(09)70068-7 (2009).","journal-title":"Lancet Neurol."},{"key":"65332_CR3","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/mds.22759","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser, R. A., Auinger, P. & Oakes, D. Levodopa response in early Parkinson\u2019s disease. Mov. Disord. 24, 2328\u20132336, https:\/\/doi.org\/10.1002\/mds.22759 (2009).","journal-title":"Mov. Disord."},{"issue":"Suppl 2","key":"65332_CR4","doi-asserted-by":"publisher","first-page":"II19","DOI":"10.1007\/s00415-002-1204-4","volume":"249","author":"R Katzenschlager","year":"2002","unstructured":"Katzenschlager, R. & Lees, A. J. Treatment of Parkinson\u2019s disease: Levodopa as the first choice. J. Neurol. 249(Suppl 2), II19\u2013II24, https:\/\/doi.org\/10.1007\/s00415-002-1204-4 (2002).","journal-title":"J. Neurol."},{"key":"65332_CR5","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.1002\/mds.22037","volume":"23","author":"JG Nutt","year":"2008","unstructured":"Nutt, J. G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23, S580\u2013584, https:\/\/doi.org\/10.1002\/mds.22037 (2008).","journal-title":"Mov. Disord."},{"key":"65332_CR6","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.metabol.2014.10.030","volume":"64","author":"DB Miller","year":"2015","unstructured":"Miller, D. B. & O\u2019Callaghan, J. P. Biomarkers of Parkinson\u2019s disease: Present and future. Metabolism 64, S40\u2013S46, https:\/\/doi.org\/10.1016\/j.metabol.2014.10.030 (2015).","journal-title":"Metabolism"},{"key":"65332_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/425589","volume":"75","author":"J Chen","year":"2004","unstructured":"Chen, J. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Gene 75, 807\u2013821, https:\/\/doi.org\/10.1086\/425589 (2004).","journal-title":"Am. J. Hum. Gene"},{"key":"65332_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1006\/bbrc.1996.1731","volume":"228","author":"F Hoda","year":"1996","unstructured":"Hoda, F. et al. No association between Parkinson\u2019s disease and low-activity alleles of catechol-O-methyltransferase. Biochem. Biophys. Res. Commun. 228, 780\u2013784, https:\/\/doi.org\/10.1006\/bbrc.1996.1731 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"65332_CR9","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1126\/science.1131262","volume":"314","author":"AG Nackley","year":"2006","unstructured":"Nackley, A. G. et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314, 1930\u20131933, https:\/\/doi.org\/10.1126\/science.1131262 (2006).","journal-title":"Science"},{"key":"65332_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40291-013-0066-z","volume":"18","author":"B Yin","year":"2013","unstructured":"Yin, B., Chen, Y. & Zhang, L. Association between Catechol-O-Methyltransferase (COMT) gene polymorphisms, Parkinson\u2019s disease, and levodopa efficacy. Mol. Diagn. Ther. 18, 253\u2013260, https:\/\/doi.org\/10.1007\/s40291-013-0066-z (2013).","journal-title":"Mol. Diagn. Ther."},{"key":"65332_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0081-9","volume":"26","author":"Q Xiao","year":"2017","unstructured":"Xiao, Q., Qian, Y., Liu, J., Xu, S. & Yang, X. Roles of functional catechol-O- methyltransferase genotypes in Chinese patients with Parkinson\u2019s disease. Transl. Neurodegener. 26, 6\u201311, https:\/\/doi.org\/10.1186\/s40035-017-0081-9 (2017).","journal-title":"Transl. Neurodegener."},{"key":"65332_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/mds.20410","volume":"20","author":"M Contin","year":"2005","unstructured":"Contin, M., Martinelli, P., Mochi, M., Riva, R., Albani, F. & Baruzzi, A. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson\u2019s disease. Mov. Disord. 20, 734\u2013739, https:\/\/doi.org\/10.1002\/mds.20410 (2005).","journal-title":"Mov. Disord."},{"key":"65332_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/FPC.0b013e328306c2f2","volume":"18","author":"M Bialecka","year":"2008","unstructured":"Bialecka, M., Kurzawski, M., Klodowska-Duda, G., Opala, G., Tan, E. K. & Drozdzik, M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson\u2019s disease, levodopa treatment response, and complications. Pharmacogenet Genomics 18, 815\u2013821, https:\/\/doi.org\/10.1097\/FPC.0b013e328306c2f2 (2008).","journal-title":"Pharmacogenet Genomics"},{"key":"65332_CR14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn, S. et al. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351, 2498\u20132508, https:\/\/doi.org\/10.1056\/NEJMoa033447 (2004).","journal-title":"N. Engl. J. Med."},{"key":"65332_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10072-014-1998-8","volume":"36","author":"J Liu","year":"2015","unstructured":"Liu, J., Chen, P., Guo, M., Lu, L. & Li, L. Association of COMT Val158Met polymorphism with wearing-off susceptibility in Parkinson\u2019s disease. Neurol. Sci. 36, 621\u2013623, https:\/\/doi.org\/10.1007\/s10072-014-1998-8 (2015).","journal-title":"Neurol. Sci."},{"key":"65332_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.parkreldis.2014.06.021","volume":"20","author":"H Hao","year":"2014","unstructured":"Hao, H. et al. Chinese Parkinson Study Group. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson\u2019s disease in a Chinese population. Parkinsonism Relat. Disord. 20, 1041\u20131045, https:\/\/doi.org\/10.1016\/j.parkreldis.2014.06.021 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"65332_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/mds.23805","volume":"27","author":"LM de Lau","year":"2012","unstructured":"de Lau, L. M., Verbaan, D., Marinus, J., Heutink, P. & van Hilten, J. J. Catechol-O- methyltransferase Val158Met and the risk of dyskinesias in Parkinson\u2019s disease. Mov. Disord. 27, 132\u2013135, https:\/\/doi.org\/10.1002\/mds.23805 (2012).","journal-title":"Mov. Disord."},{"key":"65332_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.18433\/jpps29903","volume":"21","author":"SA Ivanova","year":"2018","unstructured":"Ivanova, S. A. et al. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. J. Pharm. Pharm Sci. 21, 340\u2013346, https:\/\/doi.org\/10.18433\/jpps29903 (2018).","journal-title":"J. Pharm. Pharm Sci."},{"key":"65332_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FPC.0000000000000056","volume":"24","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2014","unstructured":"Jim\u00e9nez-Jim\u00e9nez, F. J., Alonso-Navarro, H., Garc\u00eda-Mart\u00edn, E. & Ag\u00fandez, J. A. COMT gene and risk for Parkinson\u2019s disease:a systematic review and meta-analysis. Pharmacogenet Genomics 24, 331\u2013339, https:\/\/doi.org\/10.1097\/FPC.0000000000000056 (2014).","journal-title":"Pharmacogenet Genomics"},{"key":"65332_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/01616412.2018.1564183","volume":"41","author":"YC Wang","year":"2019","unstructured":"Wang, Y. C. et al. COMT Val158Met polymorphism and Parkinson\u2019s disease risk: a pooled analysis in differentpopulations. Neurol. Res. 41, 319\u2013325, https:\/\/doi.org\/10.1080\/01616412.2018.1564183 (2019).","journal-title":"Neurol. Res."},{"key":"65332_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10072-014-1896-0","volume":"36","author":"L Chuan","year":"2015","unstructured":"Chuan, L., Gao, J., Lei, Y., Wang, R., Lu, L. & Zhang, X. Val 158 Met polymorphism of COMT gene and Parkinson\u2019s disease risk in Asians. Neurol. Sci. 36, 109\u2013115, https:\/\/doi.org\/10.1007\/s10072-014-1896-0 (2015).","journal-title":"Neurol. Sci."},{"key":"65332_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.npp.1300997","volume":"3","author":"J Beuten","year":"2006","unstructured":"Beuten, J., Payne, T. J., Ma, J. Z. & Li, M. D. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 3, 675\u2013884, https:\/\/doi.org\/10.1038\/sj.npp.1300997 (2006).","journal-title":"Neuropsychopharmacology"},{"key":"65332_CR23","first-page":"165","volume":"39","author":"SE Daniel","year":"1993","unstructured":"Daniel, S. E. & Lees, A. J. Parkinson\u2019s disease society brain bank, London: overview and research. J. Neural Transm. Suppl. 39, 165\u2013172 (1993).","journal-title":"J. Neural Transm. Suppl."},{"key":"65332_CR24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R. & Clarke, C. E. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653, https:\/\/doi.org\/10.1002\/mds.23429 (2010).","journal-title":"Mov. Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65332-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:26:30Z","timestamp":1670329590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65332-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65332"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65332-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"25 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9521"}}